Eckert & Ziegler Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Harald Hasselmann

İcra Kurulu Başkanı

€475.2k

Toplam tazminat

CEO maaş yüzdesi	65.7%
CEO görev süresi	7.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Harald Hasselmann'un ücretlendirmesi Eckert & Ziegler'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	€38m
Jun 30 2024	n/a	n/a	€38m
Mar 31 2024	n/a	n/a	€34m
Dec 31 2023	€475k	€312k	€30m
Sep 30 2023	n/a	n/a	€31m
Jun 30 2023	n/a	n/a	€29m
Mar 31 2023	n/a	n/a	€30m
Dec 31 2022	€543k	€250k	€31m
Sep 30 2022	n/a	n/a	€27m
Jun 30 2022	n/a	n/a	€27m
Mar 31 2022	n/a	n/a	€27m
Dec 31 2021	€509k	€216k	€35m
Sep 30 2021	n/a	n/a	€33m
Jun 30 2021	n/a	n/a	€31m
Mar 31 2021	n/a	n/a	€30m
Dec 31 2020	€400k	€209k	€21m
Sep 30 2020	n/a	n/a	€21m
Jun 30 2020	n/a	n/a	€22m
Mar 31 2020	n/a	n/a	€21m
Dec 31 2019	€366k	€204k	€22m
Sep 30 2019	n/a	n/a	€22m
Jun 30 2019	n/a	n/a	€21m
Mar 31 2019	n/a	n/a	€20m
Dec 31 2018	€347k	€196k	€16m
Sep 30 2018	n/a	n/a	€16m
Jun 30 2018	n/a	n/a	€14m
Mar 31 2018	n/a	n/a	€11m
Dec 31 2017	€345k	€189k	€12m

Tazminat ve Piyasa: Harald 'nin toplam tazminatı ($USD 500.22K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.47M ).

Tazminat ve Kazançlar: Harald 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Harald Hasselmann (57 yo)

7.8yrs

Görev süresi

€475,161

Tazminat

Dr. Harald Hasselmann was Deputy Chairman of the Supervisory Board of Pentixapharm Holding AG from February 15, 2024 until 2024. Dr. Hasselmann is Chairman of the Executive Board of Medical Segment at Ecke...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harald Hasselmann	CEO & Chairman of the Executive Board of Medical Segment	7.8yrs	€475.16k	Veri yok
Franklin Yeager	President of Eckert and Ziegler Isotope Products Inc. & Member of Executive Board	1.4yrs	€1.12m	Veri yok
Jutta Ludwig	Member of Executive Board of Asia Business	1.8yrs	€181.48k	Veri yok
Gunnar Mann	Head of Intragroup Services	12.8yrs	Veri yok	Veri yok
Ana Ramirez	Head of Segment Isotope Products	less than a year	Veri yok	Veri yok
Ivan Simmer	Managing Director of Eckert & Ziegler Cesio s.r.o.	10.8yrs	Veri yok	Veri yok
Joseph Hathcock	Vice President of Eckert & Ziegler Isotope Products Inc.	no data	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 0NZY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andreas Eckert	Chairman of the Supervisory Board	less than a year	€700.71k	0.000020% € 159.2
Frank Perschmann	Member of Supervisory Board	5.5yrs	€37.92k	Veri yok
Edgar Löffler	Member of Supervisory Board	5.8yrs	€34.58k	Veri yok
Helmut Grothe	Deputy Chairman of the Supervisory Board	10.3yrs	€39.00k	Veri yok
Paola Eckert-Palvarini	Member of Supervisory Board	1.9yrs	Veri yok	Veri yok
Albert Rupprecht	Member of Supervisory Board	7.5yrs	€37.67k	Veri yok

5.7yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0NZY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Eckert & Ziegler Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Eckert & Ziegler AG Announces Executive Changes

Eckert & Ziegler Strahlen- und Medizintechnik AG, Annual General Meeting, May 28, 2024

Eckert & Ziegler Strahlen- und Medizintechnik AG Announces Management Changes

Eckert & Ziegler Strahlen- und Medizintechnik AG, Annual General Meeting, Jun 07, 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG, Annual General Meeting, Jun 02, 2021

Recent updates

Third quarter 2024 earnings released: EPS: €0.45 (vs €0.45 in 3Q 2023)

Eckert & Ziegler SE to Report Q1, 2025 Results on May 13, 2025

Second quarter 2024 earnings released: EPS: €0.52 (vs €0.30 in 2Q 2023)

Upcoming dividend of €0.05 per share

Upcoming dividend of €0.05 per share

First quarter 2024 earnings released: EPS: €0.43 (vs €0.23 in 1Q 2023)

Full year 2023 earnings released: EPS: €1.44 (vs €1.41 in FY 2022)

Dividend of €0.05 announced

Eckert & Ziegler AG Announces Executive Changes

Third quarter 2023 earnings released: EPS: €0.45 (vs €0.38 in 3Q 2022)

Eckert & Ziegler Strahlen- Und Medizintechnik Ag Confirms Earnings Guidance for the Year 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG, Annual General Meeting, May 28, 2024

Second quarter 2023 earnings released: EPS: €0.30 (vs €0.43 in 2Q 2022)

Eckert & Ziegler Strahlen- und Medizintechnik AG Provides Earnings Guidance for the Year 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG Announces Management Changes

Upcoming dividend of €0.50 per share at 1.3% yield

First quarter 2023 earnings released: EPS: €0.23 (vs €0.32 in 1Q 2022)

Investor sentiment deteriorates as stock falls 21%

Eckert & Ziegler Strahlen- und Medizintechnik AG Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Eckert & Ziegler Strahlen- und Medizintechnik AG (XTRA:EUZ) acquired unknown majority stake in Myelo Therapeutics GmbH from ELSA 2 Beteiligungen GmbH, and founders.

Third quarter 2022 earnings released: EPS: €0.38 (vs €0.34 in 3Q 2021)

Eckert & Ziegler Strahlen- und Medizintechnik AG, Annual General Meeting, Jun 07, 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG Berlin Ordinary Shares to Be Deleted from OTC Equity

Second quarter 2022 earnings released: EPS: €0.43 (vs €0.41 in 2Q 2021)

Eckert & Ziegler Strahlen- und Medizintechnik AG Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Eckert & Ziegler Strahlen- und Medizintechnik AG Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

Upcoming dividend of €0.50 per share

First quarter 2022 earnings released: EPS: €0.32 (vs €0.67 in 1Q 2021)

Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Year 2022

Eckert & Ziegler Strahlen- Und Medizintechnik AG Provides Earnings Guidance for the First Quarter of 2022

Full year 2021 earnings released: EPS: €1.67 (vs €1.11 in FY 2020)

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Eckert & Ziegler Strahlen- und Medizintechnik AG (XTRA:EUZ) acquired Tecnonuclear S. A.

Third quarter 2021 earnings released: EPS €0.34 (vs €0.24 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS €0.41 (vs €0.37 in 2Q 2020)

Upcoming dividend of €0.45 per share

Investor sentiment improved over the past week

First quarter 2021 earnings released

Eckert & Ziegler Strahlen- und Medizintechnik AG Provides Financial Guidance for 2021

Eckert & Ziegler AG Revises Earnings Guidance for the Year 2020

Eckert & Ziegler Wins Order for Hot Cell Construction from Dutch Research Center

New 90-day high: €57.65

Investor sentiment improved over the past week

New 90-day high: €46.20

Eckert & Ziegler Strahlen- und Medizintechnik AG, Annual General Meeting, Jun 02, 2021

Third quarter 2020 earnings released: EPS €0.24

New 90-day high: €44.32

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of Licensed radiopharmaceutical production facility in Seneffe from Eckert & Ziegler Strahlen- und Medizintechnik AG (XTRA:EUZ)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş